Research progress of donor NK cells and chimerism in allogeneic hematopoietic stem cell transplantation

doi:10.3877/cma.j.issn.1674-3903.2018.02.010

Abstract

Abstract:

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been widely used for the treatment of hematopoietic diseases, nonetheless, major challenges persist, including a series of complications. The application of natural killer (NK) cells brings hope for improving the prognosis of patients after allo-HSCT. Killer cell immunoglobulin-like receptors (KIR) located on cytomembrane of donor NK cells and KIR-ligands mismatch plays a role in promoting the alloreactivity of NK cells, which maintains graft versus leukemia effects while reducing graft versus host disease. NK cells is the first immune cell subset to recover after allo-HSCT, so the monitoring of NK cells chimerism plays an significant role in predicting the prognosis of diseases and the intervention treatment. Furthermore, NK cells infusion based on chimerism is likely to improve the prognosis, which shows a broad application prospect in hematopoietic diseases. This article is to review the research progress of aforementioned aspects.

Key words: Allogeneic hematopoietic stem cell transplantation, Natural killer cell, Alloreactivity, Chimerism, Graft versus host disease, Graft rejection

Fang Yang, Lixia Sheng, Guifang Ouyang. Research progress of donor NK cells and chimerism in allogeneic hematopoietic stem cell transplantation[J]. Chinese Journal of Transplantation(Electronic Edition), 2018, 12(02): 91-96.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhyzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3903.2018.02.010

https://zhyzzz.cma-cmc.com.cn/EN/Y2018/V12/I02/91

References 44

1	Servais S,Beguin Y,Baron F. Emerging drugs for prevention of graft failure after allogeneic hematopoietic stem cell transplantation[J]. Expert Opin Emerg Drugs, 2013, 18(2): 173-192.
2	Olson JA,Leveson-Gower DB,Gill S, et al. NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects[J]. Blood, 2010, 115(21): 4293-4301.
3	Montaldo E,Del Zotto G,Della Chiesa M, et al. Human NK cell receptors/markers: a tool to analyze NK cell development, subsets and function[J]. Cytometry A, 2013, 83(8): 702-713.
4	Pietra G,Vitale C,Pende D, et al. Human natural killer cells: news in the therapy of solid tumors and high-risk leukemias[J]. Cancer Immunol Immunother, 2016, 65(4): 465-476.
5	万露露,张斌,胡亮钉. 自然杀伤细胞预防急性移植物抗宿主病相关研究进展[J]. 中国实用内科杂志，2015, 35(11): 957-960.
6	Davies JOJ,Stringaris K,Barrett AJ, et al. Opportunities and limitations of natural killer cells as adoptive therapy for malignant disease[J]. Cytotherapy, 2014, 16(11): 1453-1466.
7	王平忠,于海涛,蒋伟，等. 自然杀伤细胞受体介导抗病毒免疫的分子机制[J]. 细胞与分子免疫学杂志，2013，29(4): 441-443.
8	Benjamin JE,Gill S,Negrin RS. Biology and clinical effects of natural killer cells in allogeneic transplantation[J]. Curr Opin Oncol, 2010，22(2): 130-137.
9	Willemze R,Ruggeri A,Purtill D, et al. Is there an impact of killer cell immunoglobulin-like receptors and KIR-ligand incompatibilities on outcomes after unrelated cord blood stem cell transplantation[J]. Best Pract Res Clin Haematol, 2010, 23(2): 283-290.
10	Minculescu L,Marquart HV,Friis LS, et al. Early NK cell reconstitution predicts overall survival in T-cell replete allogeneic hematopoietic stem cell transplantation[J]. Biol Blood Marrow Transplant, 2016, 22(12): 2187-2193.
11	Cooley S,Parham P,Miller JS. Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation[J]. Blood, 2018，131(10): 1053-1062.
12	程杰,孙自敏,刘会兰，等. 急性白血病患者非血缘脐血干细胞移植后NK细胞及其表面受体的早期重建[J]. 中国实验血液学杂志，2009, 17(2): 426-430.
13	Ullrich E,Salzmann-Manrique E,Bakhtiar S, et al. Relation between acute GVHD and NK cell subset reconstitution following allogeneic stem cell transplantation[J]. Front Immunol, 2016, 7: 595.
14	Mancusi A,Ruggeri L,Urbani E, et al. Haploidentical hematopoietic transplantation from KIR ligand-mismatched donors with activating KIRs reduces nonrelapse mortality[J]. Blood, 2015, 125(20): 3173-3182.
15	Moretta L,Pietra G,Vacca P, et al. Human NK cells: From surface receptors to clinical applications[J]. Immunol Lett, 2016, 178: 15-19.
16	Sun JC. Re-educating natural killer cells[J]. J Exp Med, 2010, 207(10): 2049-2052.
17	Suck G,Linn YC,Tonn T. Natural killer cells for therapy of leukemia[J]. Transfus Med Hemother, 2016, 43(2): 89-95.
18	Hartman KG,Bortner JD,Falk GW, et al. Modeling human gastrointestinal inflammatory diseases using microphysiological culture systems[J]. Exp Biol Med (Maywood), 2014，239(9): 1108-1123.
19	Blazar BR,Murphy WJ,Abedi M. Advances in graf-versus-host disease biology and therapy[J]. Nat Rev Immunol, 2012, 12(6): 443-458.
20	Ljungman P,Brand R,Hoek J, et al. Donor CMV status influences the outcome of allogeneic stem cell transplantation; a study by the European group for blood and marrow transplantation[J]. Clin Infect Dis, 2014, 59(4): 473-481.
21	Huenecke S,Cappel C,Esser R, et al. Development of three different NK cell subpopulations during immune reconstitution after pediatric allogeneic hematopoietic stem cell transplantation: prognostic markers in GVHD and viral infections[J]. Front Immunol, 2017, 8: 109.
22	Merzoni J,Ewald GM,Paz AA, et al. Quantification of mixed chimerism allows early therapeutic interventions[J]. Rev Bras Hematol Hemoter, 2014, 36(5): 369-372.
23	Baron F,Sandmaier BM. Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning[J]. Leukemia, 2006, 20(10): 1690-1700.
24	万理萍,王椿,蒋瑛，等. 同种异基因造血干细胞移植后基于血细胞嵌合状态的个体化免疫治疗[J]. 诊断学理论与实践，2010, 9(1): 25-30.
25	Moscardó F,Sanz J,Senent L, et al. Impact of hematopoietic chimerism at day ＋14 on engraftment after unrelated donor umbilical cord blood transplantation for hematologic malignancies[J]. Haematologica, 2009, 94(6): 827-832.
26	洪睿敏,盛立霞,黄河，等. 各系免疫细胞嵌合状态监测在异基因造血干细胞移植后的意义[J/CD]．中华移植杂志：电子版，2017，11(4): 245-250.
27	Stikvoort A,Sundin M,Uzunel M, et al. Long-term stable mixed chimerism after hematopoietic stem cell transplantation in patients with non-malignant disease, shall we be tolerant[J]. PLoS One, 2016, 11(5): e0154737.
28	Reshef R,Hexner EO,Loren AW, et al. Early donor chimerism levels predict relapse and survival after allogeneic stem cell transplantation with reduced-intensity conditioning[J]. Biol Blood Marrow Transplant, 2014, 20(11): 1758-1766.
29	苏秀华. 异基因造血干细胞移植后嵌合状态的研究进展[J]. 国际输血及血液学杂志，2015, 38(5): 406-410.
30	Childs R,Clave E,Contentin N, et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses[J]. Blood, 1999, 94(9): 3234-3241.
31	Breuer S,Preuner S,Fritsch G, et al. Early recipient chimerism testing in the T- and NK-cell lineages for risk assessment of graft rejection in pediatric patients undergoing allogeneic stem cell transplantation[J]. Leukemia, 2012, 26(3): 509-519.
32	Baggio L,Laureano ÁM,LMDR S, et al. Natural killer cell adoptive immunotherapy: Coming of age[J]. Clin Immunol, 2017, 177: 3-11.
33	陈广华,吴德沛,孙爱宁，等. IL-2和IL-15激活供者自然杀伤细胞在异基因造血干细胞移植应用的实验研究[J]. 中华血液学杂志，2008, 29(8): 526-530.
34	Childs RW,Carlsten M. Terapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens[J]. Nat Rev Drug Discov, 2015, 14(7): 487-498.
35	Dolstra H,Roeven MWH,Spanholtz J, et al. Successful transfer of umbilical cord blood CD34^＋ hematopoietic stem and progenitor-derived NK cells in older acute myeloid leukemia patients[J]. Clin Cancer Res, 2017, 23(15): 4107-4118.
36	Rubnitz JE,Inaba H,Kang G, et al. Natural killer cell therapy in children with relapsed leukemia[J]. Pediatr Blood Cancer, 2015, 62(8): 1468-1472.
37	Terwey TH,Hemmati PG,Nagy M, et al. Comparison of chimerism and minimal residual disease monitoring for relapse prediction after allogeneic stem cell transplantation for adult acute lymphoblastic leukemia[J]. Biol Blood Marrow Transplant, 2014, 20(10): 1522-1529.
38	Liga M,Triantafyllou E,Tiniakou M, et al. High alloreactivity of low-dose prophylactic donor lymphocyte infusion in patients with acute leukemia undergoing allogeneic hematopoietic cell transplantation with an alemtuzumab-containing conditioning regimen[J]. Biol Blood Marrow Transplant, 2013, 19(1): 75-81.
39	Passweg JR,Tichelli A,Meyer-Monard S, et al. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation[J]. Leukemia, 2004, 18(11): 1835-1838.
40	Ciurea SO,Schafer JR,Bassett R, et al. Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation[J]. Blood, 2017, 130(16): 1857-1868.
41	Locatelli F,Merli P,Rutella S. At the bedside: Innate immunity as an immunotherapy tool for hematological malignancies[J]. J Leukoc Biol, 2013, 94(6): 1141-1157.
42	Parmar S,Fernandez-Vina M,de Lima M. Novel transplant strategies for generating graft-versus-leukemia effect in acute myeloid leukemia[J]. Curr Opin Hematol, 2011, 18(2): 98-104.
43	Shaffer BC,Le Luduec JB,Forlenza C, et al. Phase Ⅱ study of haploidentical natural killer cell infusion for treatment of relapsed or persistent myeloid malignancies following allogeneic hematopoietic cell transplantation[J]. Biol Blood Marrow Transplant, 2016, 22(4): 705-709.
44	Vela M,Corral D,Carrasco P, et al. Haploidentical IL-15/41BBL activated and expanded natural killer cell infusion therapy after salvage chemotherapy in children with relapsed and refractory leukemia[J]. Cancer Letters, 2018, 422: 107-117.

[1]	Yonghui Zhong, Fuchuan Xie, Yisheng Wei. Effect of colon cancer derived exosomes on the expression of miR-18a and NKG2D in natural killer cells [J]. Chinese Archives of General Surgery(Electronic Edition), 2021, 15(03): 172-177.
[2]	Xin Kong, Baoquan Song, Yin Liu, Jian Zhang, Huiying Qiu, Depei Wu. Intractable hiccup induced by allogeneic hematopoietic stem cell transplantation: a case report [J]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(04): 253-255.
[3]	min Chen, Tianzhong Pan, Zimin Sun. Iron removal therapy for poor implantation after allogeneic hematopoietic stem cell transplantation: a case report [J]. Chinese Journal of Transplantation(Electronic Edition), 2022, 16(03): 168-171.
[4]	Jing Zhao, Shuyi Ding, Xiaoyu Zhou, Jianli Zhang, Liwei Xu, Lichen Zhang, Jiali Yan, Qiong Cheng, Nian Liu, Aiyun Jin. The variation and impact factors of quality of life in chronic graft versus host disease patients after allogeneic hematopoietic stem cell transplantation [J]. Chinese Journal of Transplantation(Electronic Edition), 2022, 16(03): 153-159.
[5]	Heng Liu, Tao Wu. Research progress of ibrutinib in the treatment of chronic graft-versus-host disease [J]. Chinese Journal of Transplantation(Electronic Edition), 2021, 15(05): 317-320.
[6]	Yan Liu, Tao Wu, Dongfeng Mao, Lingling Yu, Hai Bai. A case report of human leukocyte antigen matched allogenetic hematopoietic stem cell transplantation in the treatment of refractory polygenic mutation in acute myeloid leukemia [J]. Chinese Journal of Transplantation(Electronic Edition), 2021, 15(04): 229-231.
[7]	Chaolang Zhang, Xiaoping Guo, Fenying Zhao, Xiaojun Xu. Infantile diarrhea accompanied with regenerating islet-derived protein 3 alpha elevation after allogeneic hematopoietic stem cell transplantation: two cases report [J]. Chinese Journal of Transplantation(Electronic Edition), 2021, 15(02): 116-118.
[8]	Yong Zhang, Hebing Zhou. B cell lymphoma/leukemia-2 inhibitor plus azacytidine regimen for two cases of relapse acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation [J]. Chinese Journal of Transplantation(Electronic Edition), 2021, 15(01): 45-48.
[9]	Wenhui Liu, Tao Wu, Xi Zhang. Advances in mesenchymal stem cells combined with thrombopoietin receptor agonists in platelet recovery after allogeneic hematopoietic stem cell transplantation [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2023, 13(04): 242-246.
[10]	Wei Du, Lijuan Cui, Ying Xu, Hua Zhang, Hongwei Du, Jinmei Zhang, Rongzhi Liu, Zhengyu Wang, Wenling Yang, Yu Zhang. Biological characteristics of natural killer cells from cord blood mononuclear cell-derived induced pluripotent stem cells [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2021, 11(06): 329-336.
[11]	Luning Liu, Xuemei Chen, Enqi Ma, Qingyan Tian, Qianqian Liu, Tao Liu. Effects of human CD137 antibody on specific cytotoxicity in NK cells against breast cancer cells in vitro [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2020, 10(06): 346-353.
[12]	Xiaoning Wang, Ying Zhang, Xinwei Liu, Juan Ren, Jieying Xi, Pengcheng He. Clinical analysis of steroid-resistant acute gastrointestinal graft versus host disease after allogeneic hematopoietic stem cell transplantation [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2020, 10(06): 336-340.
[13]	Tianhua Tan, Jinghai Song. Research progress of natural killer cell and related immunotherapy for hepatocellular carcinoma [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(02): 243-246.
[14]	Huining Cai, Shiyu Qian, Weicai Chen, Mengchun Huang, Wenjie Chen, Jianxi Lu. Cytotoxic effect of peripheral blood NK cell proliferation in vitro on different tumor cell lines [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2022, 11(04): 411-415.
[15]	Jie Zhao, Lan Wang, Hongmei Yang, Yi He, Hong Yuan. Autoimmune hemolytic anemia following allogeneic hematopoietic stem cell transplantation in a patient: serological detection methods for mimicking antibodies and blood transfusion strategy [J]. Chinese Journal of Clinicians(Electronic Edition), 2022, 16(05): 452-456.

Please choose a citation manager

Content to export